Get the Stockscreener App
1.03
3.00%
0.03
After Hours:
1.04
0.01
+0.97%
Fate Therapeutics Inc stock is traded at $1.03, with a volume of 1.07M.
It is up +3.00% in the last 24 hours and down -32.68% over the past month.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
See More
Previous Close:
$1.00
Open:
$1
24h Volume:
1.07M
Relative Volume:
0.50
Market Cap:
$118.81M
Revenue:
$13.45M
Net Income/Loss:
$-178.23M
P/E Ratio:
-0.6242
EPS:
-1.65
Net Cash Flow:
$-132.53M
1W Performance:
+6.85%
1M Performance:
-32.68%
6M Performance:
-11.97%
1Y Performance:
-50.24%
1-Day Range:
$0.9651
$1.045
1-Week Range:
$0.96
$1.105
52-Week Range:
$0.6611
$3.43
Fate Therapeutics Inc Stock (FATE) Company Profile
Name
Fate Therapeutics Inc
Sector
Industry
Phone
858.875.1803
Address
12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA
Compare FATE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FATE
Fate Therapeutics Inc
|
1.03 | 115.35M | 13.45M | -178.23M | -132.53M | -1.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-31-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-27-25 | Upgrade | Wedbush | Neutral → Outperform |
| Nov-18-24 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-17-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-27-23 | Resumed | Wells Fargo | Equal Weight |
| Jan-24-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jan-06-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jan-06-23 | Downgrade | BofA Securities | Buy → Underperform |
| Jan-06-23 | Downgrade | Cowen | Outperform → Market Perform |
| Jan-06-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-06-23 | Downgrade | Stifel | Buy → Hold |
| Jan-06-23 | Downgrade | Truist | Buy → Hold |
| Jan-06-23 | Downgrade | Wedbush | Outperform → Neutral |
| Jan-03-23 | Downgrade | Guggenheim | Buy → Neutral |
| Dec-22-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-15-22 | Initiated | Goldman | Sell |
| Nov-04-22 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-10-22 | Initiated | Canaccord Genuity | Buy |
| Aug-18-22 | Resumed | Wells Fargo | Overweight |
| Jul-28-22 | Initiated | Needham | Hold |
| Jul-11-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jun-03-22 | Initiated | Robert W. Baird | Neutral |
| Feb-11-22 | Resumed | BMO Capital Markets | Market Perform |
| Dec-15-21 | Upgrade | Wedbush | Neutral → Outperform |
| Dec-07-21 | Initiated | Cowen | Outperform |
| Nov-09-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-26-21 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-07-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-07-21 | Upgrade | Wedbush | Neutral → Outperform |
| Apr-26-21 | Resumed | Jefferies | Buy |
| Feb-26-21 | Initiated | BofA Securities | Buy |
| Feb-26-21 | Downgrade | Wedbush | Outperform → Neutral |
| Feb-11-21 | Downgrade | Citigroup | Buy → Neutral |
| Jan-27-21 | Resumed | H.C. Wainwright | Neutral |
| May-13-20 | Initiated | H.C. Wainwright | Buy |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-09-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-30-19 | Reiterated | Mizuho | Buy |
| Dec-09-19 | Upgrade | Wells Fargo | Market Perform → Outperform |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Nov-06-19 | Downgrade | Wells Fargo | Outperform → Market Perform |
| Oct-01-19 | Initiated | Stifel | Buy |
| Aug-09-19 | Initiated | BTIG Research | Buy |
| Jul-22-19 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-12-19 | Initiated | Oppenheimer | Outperform |
| Jun-13-19 | Initiated | Mizuho | Buy |
| Jun-07-19 | Initiated | ROTH Capital | Neutral |
| May-31-19 | Initiated | Guggenheim | Buy |
| May-24-19 | Resumed | Citigroup | Buy |
| Mar-28-19 | Initiated | SVB Leerink | Outperform |
| Jan-03-19 | Downgrade | Stephens | Overweight → Equal-Weight |
| Nov-05-18 | Initiated | Jefferies | Buy |
| Aug-01-18 | Initiated | Citigroup | Buy |
| Mar-06-18 | Downgrade | H.C. Wainwright | Buy → Neutral |
View All
Fate Therapeutics Inc Stock (FATE) Latest News
Cantor Fitzgerald Issues Positive Outlook for FATE Earnings - MarketBeat
Multi factor analysis applied to Fate Therapeutics Inc.July 2025 Action & Free Growth Oriented Trading Recommendations - newser.com
Tools to monitor Fate Therapeutics Inc. recovery probabilityBuy Signal & Growth Oriented Trade Recommendations - newser.com
Automated trading signals detected on Fate Therapeutics Inc.Short Setup & Accurate Buy Signal Alerts - newser.com
Will Fate Therapeutics Inc. stock outperform Nasdaq indexQuarterly Portfolio Report & Precise Entry and Exit Recommendations - newser.com
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Fate Therapeutics (FATE), ALX Oncology Holdings (ALXO) and 60 Degrees Pharmaceuticals, Inc. (SXTP) - The Globe and Mail
Is Fate Therapeutics Inc. stock undervalued vs historical averagesEarnings Trend Report & Capital Efficient Trade Techniques - newser.com
Exit strategy if you’re trapped in Fate Therapeutics Inc.Portfolio Return Summary & Daily Entry Point Trade Alerts - newser.com
Will Fate Therapeutics Inc. see short term momentumEarnings Risk Summary & Real-Time Volume Spike Alerts - newser.com
Fate Therapeutics, Inc. (NASDAQ:FATE) Given Average Rating of "Hold" by Brokerages - MarketBeat
Fate Therapeutics Reports Q3 Loss Amid Restructuring Efforts - TipRanks
How sentiment analysis helps forecast Fate Therapeutics Inc.2025 Pullback Review & Free Growth Oriented Trading Recommendations - newser.com
Published on: 2025-11-16 18:05:52 - newser.com
Will Fate Therapeutics Inc. stock recover faster than market2025 EndofYear Setup & Safe Entry Zone Tips - newser.com
Fate Therapeutics (FATE) Receives a Hold from Bank of America Securities - The Globe and Mail
Navigating Data Privacy Challenges: Fate Therapeutics’ Battle with Regulatory Compliance and Business Risks - TipRanks
Why Fate Therapeutics Inc. stock remains a top recommendationPortfolio Gains Report & Verified Stock Trade Ideas - newser.com
How resilient is Fate Therapeutics Inc. stock in market downturns2025 AllTime Highs & Weekly High Return Opportunities - newser.com
Fate Therapeutics (NASDAQ:FATE) Announces Quarterly Earnings Results - MarketBeat
Fate Therapeutics: Q3 Earnings Snapshot - Connecticut Post
Analyzing drawdowns of Fate Therapeutics Inc. with statistical tools2025 Fundamental Recap & Free Fast Entry Momentum Trade Alerts - newser.com
Needham Maintains Fate Therapeutics(FATE.US) With Hold Rating - 富途牛牛
Fate Therapeutics earnings beat by $0.03, revenue topped estimates - Investing.com Canada
Fate Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
Fate Therapeutics (FATE) Reports Q3 Loss, Beats Revenue Estimates - sharewise.com
Fate Therapeutics Q3 net loss widens - MarketScreener
Fate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates - The Manila Times
FATE THERAPEUTICS INC SEC 10-Q Report - TradingView
Why Fate Therapeutics Inc. stock is a value investor pickJuly 2025 EndofMonth & Precise Entry and Exit Recommendations - newser.com
Fate Therapeutics Inc Stock (FATE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Fate Therapeutics Inc Stock (FATE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Valamehr Bahram | President and CEO |
Aug 04 '25 |
Sale |
1.06 |
14,466 |
15,396 |
334,898 |
1.38%
1.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):